GSK picks up asthma candidate from J&J

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it obtained exclusive, worldwide rights to CNTO 7160 from the Janssen Sciences Ireland UC unit of Johnson & Johnson (NYSE:JNJ). The mAb against IL-33 receptor is in a Phase I trial to treat asthma and atopic dermatitis.

Janssen is eligible for L175 million ($229.7 million) in upfront and milestone payments, plus tiered royalties. GSK is to take over development and commercialization after the Phase I study is complete. ...